---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-059136"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:28:38.825040+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Edgewise Q1 net loss $28.5M; sevasemten shows positive Becker data

## Summary
- Cash, cash equivalents and marketable securities $532.8M as of March 31, 2024.
- Net loss $28.5M ($0.33 per share) vs $30.1M ($0.47) prior quarter.
- Sevasemten ARCH 2-year: NSAA stabilized, CK and TNNI2 decreased; DUNE showed 45% CK reduction vs placebo.
- GRAND CANYON pivotal cohort recruiting ~120 patients with Becker; data expected Q4 2024.
- EDG-7500 Phase 2 CIRRUS-HCM trial initiated; first patient dosed April 2024.

## SEC filing metadata
- accession: 0001104659-24-059136
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465924059136/0001104659-24-059136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465924059136/tm2413446d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-059136
- JSON: https://secwatch.observer/filing/0001104659-24-059136.json
- Plain text: https://secwatch.observer/filing/0001104659-24-059136.txt

## Key facts
- Earnings Releases
  Edgewise Therapeutics, Inc. reported financial results for first quarter of 2024.
  - Period: first quarter of 2024
  - Result: reported results
  source text: On May 9, 2024, Edgewise Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710072/000110465924059136/0001104659-24-059136-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.